<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B6853047-0FD9-4830-AAD5-89D341EC087C"><gtr:id>B6853047-0FD9-4830-AAD5-89D341EC087C</gtr:id><gtr:firstName>Hans</gtr:firstName><gtr:surname>Stauss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2C0AE1A4-B497-4343-8EE8-FD98C852AC55"><gtr:id>2C0AE1A4-B497-4343-8EE8-FD98C852AC55</gtr:id><gtr:firstName>Emma</gtr:firstName><gtr:surname>Morris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700149"><gtr:id>E5D51704-8371-4E85-97FE-CDF9C721DAF5</gtr:id><gtr:title>Antigen-specific co-stimulation to enhance the anti-tumour activity of TCR gene modified cytotoxic T lymphocytes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700149</gtr:grantReference><gtr:abstractText>The immune system can protect individuals against virus infection and against the growth of certain types of tumours. Some human cancers are caused by viruses, which allows the immune system to recognise and eliminate the virus-infected cancer cells. Killer cells of the immune system are particularly important for this elimination, as they possess receptor molecules that allow them to specifically recognise and kill infected cancer cells.
Unfortunately, many human cancers are not caused by virus infection and therefore do not contain virus-derived markers that are recognised by killer cells. As a consequence, killer cells cannot efficiently recognise and kill such cancer cells. 
In this project we will gene modify killer cells such that they can efficiently recognise human cancer cells. We will introduce into killer cells the genes coding for two receptors that specifically recognise markers that are present in various human cancer cells. In this way, the killer cells can use two receptors and simultaneously recognise two markers present in cancer cells, which should result in efficient cancer cell killing.</gtr:abstractText><gtr:technicalSummary>Although TCR gene transfer can readily produce populations of antigen-specific T lymphocytes for adoptive cancer immunotherapy, tumour cell recognition usually occurs in the absence of co-stimulation, which may result in poor T cell stimulation in vivo. In this project we will test whether dual receptor T cells can efficiently recognise co-stimulation-deficient tumour cells. The TCR, specific for HLA presented tumour peptides will deliver signal I, while the co-stimulation signal II is delivered by chimeric single chain antibodies specific for a molecule expressed on the surface of tumour cells.
Here, we will use a chimeric single chain antibody construct that specifically binds to CD19, a marker expressed in most human B-cell malignancies. The intracellular domain of the construct has been engineered and harbours the signalling motif of CD28. The simultaneous engagement of the tumour-specific TCR and the anti-CD19 co-receptor will deliver two signals that are expected to synergise and improve T cell avidity, the production of IL2 and proliferation of effector T cells. If successful, the antigen-specific co-stimulation concept is highly versatile and can be extended to other single chain antibodies in combination with the signalling motifs of various co-stimulatory molecules such as CD27, CD28, CD134 (OX40) and CD137 (4-1BB).</gtr:technicalSummary><gtr:fund><gtr:end>2011-06-06</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>327656</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Manchester</gtr:department><gtr:description>ATTACK Integrated Consortium; EU funded</gtr:description><gtr:id>5A0110DB-34FA-4AC3-849D-40159F5654DC</gtr:id><gtr:impact>The EU network facilitated the collaboration with the University of Collogne that is important for this project.</gtr:impact><gtr:partnerContribution>Joint publications. Exchange of personnel Exchange of reagents Exchange of know how</gtr:partnerContribution><gtr:piContribution>Intellectual input Provision of models Provision of reagents Provision of know how</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Manchester</gtr:department><gtr:description>ATTRACT</gtr:description><gtr:id>62E22A85-8CD5-4642-BD7E-ECE12D514269</gtr:id><gtr:impact>appointment of a PhD student</gtr:impact><gtr:partnerContribution>This is an EU funded project coordinated from Manchester</gtr:partnerContribution><gtr:piContribution>We provide research and training expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>7E560A85-DB9E-411D-BF54-2027479EF164</gtr:id><gtr:impact>Parents attended the presentation which was followed by a lively discussion, and some individuals wanting to donate money for research.

School asked me to come back for a second presentation.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>253094</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AB01E021-137E-4A7B-A0EC-A91397B3B8B3</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>256000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5E924F6B-AB51-48E6-87BB-9DACD503797C</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230607</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>649A8F62-219D-4666-9B9B-37A3CEF5179E</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The function of gene modified T cells was enhanced by co-transfer of TCR and single chain FV constructs to mediate co-stimulation.</gtr:description><gtr:id>9B14E1D5-F200-4185-97AE-7A3B6B8F70C8</gtr:id><gtr:impact>The developed technology may enhance the efficacy and specificity of TCR gene therapy</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Gene engineered T cells</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55BDBC82-0BF6-4026-AFD0-E2F6AE8AF729"><gtr:id>55BDBC82-0BF6-4026-AFD0-E2F6AE8AF729</gtr:id><gtr:title>Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fc53dfb2303f38272c47a042e0da779d"><gtr:id>fc53dfb2303f38272c47a042e0da779d</gtr:id><gtr:otherNames>Tamir A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3D49865-8815-4FB2-BE80-2E9564C54D6F"><gtr:id>E3D49865-8815-4FB2-BE80-2E9564C54D6F</gtr:id><gtr:title>Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c31326fe2d7119af01381f29a5e77427"><gtr:id>c31326fe2d7119af01381f29a5e77427</gtr:id><gtr:otherNames>Thomas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A26DE75A-A72E-494A-97B6-A62F11A17E98"><gtr:id>A26DE75A-A72E-494A-97B6-A62F11A17E98</gtr:id><gtr:title>Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette.</gtr:title><gtr:parentPublicationTitle>Journal of molecular medicine (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5e760a3f6094727c13375037d970f0c"><gtr:id>c5e760a3f6094727c13375037d970f0c</gtr:id><gtr:otherNames>Leisegang M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0946-2716</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6DD0953-3067-4F1E-A8EB-9AD557997A57"><gtr:id>B6DD0953-3067-4F1E-A8EB-9AD557997A57</gtr:id><gtr:title>Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors.</gtr:title><gtr:parentPublicationTitle>Journal of immunotherapy (Hagerstown, Md. : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/49a790dd5935ea90a9bd132b1df62812"><gtr:id>49a790dd5935ea90a9bd132b1df62812</gtr:id><gtr:otherNames>Dai MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1524-9557</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0EF436D-BE55-4B72-A015-3ED91F4AECA2"><gtr:id>B0EF436D-BE55-4B72-A015-3ED91F4AECA2</gtr:id><gtr:title>Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b999bff29ae3584c98fe490444298f8b"><gtr:id>b999bff29ae3584c98fe490444298f8b</gtr:id><gtr:otherNames>Perro M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55637806-A4B5-4EF8-900C-FD31F09837CC"><gtr:id>55637806-A4B5-4EF8-900C-FD31F09837CC</gtr:id><gtr:title>Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e9cc40c835bc89e42cadfc0f19132a6a"><gtr:id>e9cc40c835bc89e42cadfc0f19132a6a</gtr:id><gtr:otherNames>Gillmore R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A2CCDF5-02FF-4F3C-B1CF-A746C980E6DD"><gtr:id>1A2CCDF5-02FF-4F3C-B1CF-A746C980E6DD</gtr:id><gtr:title>Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ae03fe329f6f39f6142945d9f563e49"><gtr:id>6ae03fe329f6f39f6142945d9f563e49</gtr:id><gtr:otherNames>Xue SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0BD2A64B-80D9-4B08-B366-9B359605EDBC"><gtr:id>0BD2A64B-80D9-4B08-B366-9B359605EDBC</gtr:id><gtr:title>DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/759fef1dd8b2354a8d045eecfb0cf118"><gtr:id>759fef1dd8b2354a8d045eecfb0cf118</gtr:id><gtr:otherNames>Chaise C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF6954A5-10F3-4A98-84E4-5A47997E826B"><gtr:id>DF6954A5-10F3-4A98-84E4-5A47997E826B</gtr:id><gtr:title>Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c31326fe2d7119af01381f29a5e77427"><gtr:id>c31326fe2d7119af01381f29a5e77427</gtr:id><gtr:otherNames>Thomas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E5F7596F-1DCE-45D9-8820-E5C70F57E9A7"><gtr:id>E5F7596F-1DCE-45D9-8820-E5C70F57E9A7</gtr:id><gtr:title>Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ae03fe329f6f39f6142945d9f563e49"><gtr:id>6ae03fe329f6f39f6142945d9f563e49</gtr:id><gtr:otherNames>Xue SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F0A887A-4693-4EFA-9EC5-D259D66D06D4"><gtr:id>5F0A887A-4693-4EFA-9EC5-D259D66D06D4</gtr:id><gtr:title>Dendritic cell immunization induces Nonprotective WT1-specific CTL responses in mouse.</gtr:title><gtr:parentPublicationTitle>Journal of immunotherapy (Hagerstown, Md. : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c51534e4880b345ddc5c1bcb13383546"><gtr:id>c51534e4880b345ddc5c1bcb13383546</gtr:id><gtr:otherNames>Ram?rez F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1524-9557</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/223502BC-602D-4F5D-8C1B-30AA21DCF2A9"><gtr:id>223502BC-602D-4F5D-8C1B-30AA21DCF2A9</gtr:id><gtr:title>A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6de016650a30db7cb542e435097efcf5"><gtr:id>6de016650a30db7cb542e435097efcf5</gtr:id><gtr:otherNames>Bendle GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D23AD724-65CD-413D-A155-8FD6D3BF0933"><gtr:id>D23AD724-65CD-413D-A155-8FD6D3BF0933</gtr:id><gtr:title>Advances in tumour immunotherapy.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0c2f6f4b41f9b00efa45228df87b49c1"><gtr:id>0c2f6f4b41f9b00efa45228df87b49c1</gtr:id><gtr:otherNames>King J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/261862B7-EF5B-4DA4-B906-B184AB6874C0"><gtr:id>261862B7-EF5B-4DA4-B906-B184AB6874C0</gtr:id><gtr:title>Monoclonal T-cell receptors: new reagents for cancer therapy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad7f303a3a2d1f7ece5a892a3c32ad92"><gtr:id>ad7f303a3a2d1f7ece5a892a3c32ad92</gtr:id><gtr:otherNames>Stauss HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB131295-76C6-4E3C-AA99-6F144E7F5A61"><gtr:id>CB131295-76C6-4E3C-AA99-6F144E7F5A61</gtr:id><gtr:title>Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41d7ef596be4b3c17e86a591d669f56b"><gtr:id>41d7ef596be4b3c17e86a591d669f56b</gtr:id><gtr:otherNames>Wright GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F9EE2BC-289B-4AAD-AD00-616C615F21A3"><gtr:id>5F9EE2BC-289B-4AAD-AD00-616C615F21A3</gtr:id><gtr:title>WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.</gtr:title><gtr:parentPublicationTitle>Blood cells, molecules &amp; diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad7f303a3a2d1f7ece5a892a3c32ad92"><gtr:id>ad7f303a3a2d1f7ece5a892a3c32ad92</gtr:id><gtr:otherNames>Stauss HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1079-9796</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BCF8EA2B-6E03-472C-8EB0-0FBD8CC6FF32"><gtr:id>BCF8EA2B-6E03-472C-8EB0-0FBD8CC6FF32</gtr:id><gtr:title>IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/107069b077fbb6c4b8941b9da67b7b94"><gtr:id>107069b077fbb6c4b8941b9da67b7b94</gtr:id><gtr:otherNames>King JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700149</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>